Results 11 to 20 of about 46,242,060 (244)

Copper-64-Labeled Antibody Fragments for Immuno-PET/Radioimmunotherapy with Low Renal Radioactivity Levels and Amplified Tumor-Kidney Ratios. [PDF]

ACS Omega, 2021
Copper-64 (64Cu)-labeled antibody fragments such as Fab are useful for molecular imaging (immuno-PET) and radioimmunotherapy. However, these fragments cause high and persistent localization of radioactivity in the kidneys after injection.
Suzuki H, Kise S, Kaizuka Y, Watanabe R, Sugawa T, Furukawa T, Fujii H, Uehara T.   +7 more
europepmc   +2 more sources

Photoactivatable bis(thiosemicarbazone) derivatives for copper-64 radiotracer synthesis. [PDF]

Dalton Trans, 2022
In recent years, copper-64 and copper-67 have been considered as a useful theranostic pair in nuclear medicine, due to their favourable and complementary decay properties.
Earley DF, Esteban Flores J, Guillou A, Holland JP.   +3 more
europepmc   +2 more sources

Stable Radiolabeling of Sulfur-Functionalized Silica Nanoparticles with Copper-64. [PDF]

Nano Lett, 2016
Nanoparticles labeled with radiometals enable whole-body nuclear imaging and therapy. Though chelating agents are commonly used to radiolabel biomolecules, nanoparticles offer the advantage of attaching a radiometal directly to the nanoparticle itself ...
Shaffer TM, Harmsen S, Khwaja E, Kircher MF, Drain CM, Grimm J.   +5 more
europepmc   +2 more sources

Increasing Reaction Rates of Water-Soluble Porphyrins for ⁶⁴Cu Radiopharmaceutical Labeling

Molecules, 2023
Searching for new compounds and synthetic routes for medical applications is a great challenge for modern chemistry. Porphyrins, natural macrocycles able to tightly bind metal ions, can serve as complexing and delivering agents in nuclear medicine ...
Mateusz Pęgier, Krzysztof Kilian, Krystyna Pyrzynska   +2 more
doaj   +1 more source

Preparation of 64Cu-NODAGA-RGD-BBN labeled compound and its absorbed dose estimation in humans based on mouse data [PDF]

مجله علوم و فنون هسته‌ای, 2023
Calculating the absorbed dose in the human body is one of the first steps in radiopharmaceutical development. This study estimates the dose absorbed by humans from the novel identified compound of 64Cu-NODAGA-RGD-BBN.
N. Amraee, B. Alirezapour, M. Hosntalab, A. Haddadi, H. Yousefnia   +4 more
doaj   +1 more source

PESIN Conjugates for Multimodal Imaging: Can Multimerization Compensate Charge Influences on Cell Binding Properties? A Case Study

Pharmaceuticals, 2021
Recently, anionic charges were found to negatively influence the in vitro gastrin-releasing peptide receptor (GRPR) binding parameters of dually radioisotope and fluorescent dye labeled GRPR-specific peptide dimers.
Ralph Hübner, Alexa Paretzki, Valeska von Kiedrowski, Marco Maspero, Xia Cheng, Güllü Davarci, Diana Braun, Helen Damerow, Benedikt Judmann, Vasileios Filippou, Clelia Dallanoce, Ralf Schirrmacher, Björn Wängler, Carmen Wängler   +13 more
doaj   +1 more source

Design, Synthesis, and Cytotoxicity Assessment of [⁶⁴Cu]Cu-NOTA-Terpyridine Platinum Conjugate: A Novel Chemoradiotherapeutic Agent with Flexible Linker

Nanomaterials, 2021
Maximum benefits of chemoradiation therapy with platinum-based compounds are expected if the radiation and the drug are localized simultaneously in cancer cells.
Meysam Khosravifarsani, Samia Ait-Mohand, Benoit Paquette, Léon Sanche, Brigitte Guérin   +4 more
doaj   +1 more source

Copper(II) Complexes of 2,2′-Bisdipyrrins: Synthesis, Characterization, Cell Uptake, and Radiolabeling with Copper-64

, 2023
Complexes prepared with positron-emitting copper-64 are of interest as imaging agents for positron emission tomography (PET). This work investigates the potential of using acyclic tetrapyrrolic 2,2′-bisdipyrrins as ligands to prepare charge-neutral ...
Stacey E. Rudd (9237374), Jonathan M. White (1366602), Paul S. Donnelly (144955), Jacob A. Rowan (16800614), Katherine Ganio (11294574), Christopher A. McDevitt (198303)   +5 more
core   +1 more source

⁶⁴Cu-DOTHA₂-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window

Pharmaceuticals, 2022
Prostate cancer imaging and late-stage management can be improved with prostate-specific membrane antigen (PSMA)-targeting radiotracers. We developed a PSMA positron emission tomography (PET) radiotracer, DOTHA2-PSMA radiolabeled with 64Cu (T1/2: 12.7 h),
Marie-Christine Milot, Ophélie Bélissant Benesty, Véronique Dumulon-Perreault, Samia Ait-Mohand, Patrick O. Richard, Étienne Rousseau, Brigitte Guérin   +6 more
doaj   +1 more source

Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model

Frontiers in Oncology, 2023
IntroductionWe have previously shown that copper-64 (64Cu)-DOTHA2-PSMA can be used for positron emission tomography (PET) imaging of prostate cancer. Owing to the long-lasting, high tumoral uptake of 64Cu-DOTHA2-PSMA, the objective of the current study ...
Marie-Christine Milot, Ophélie Bélissant-Benesty, Véronique Dumulon-Perreault, Samia Ait-Mohand, Sameh Geha, Patrick O. Richard, Étienne Rousseau, Étienne Rousseau, Brigitte Guérin, Brigitte Guérin   +9 more
doaj   +1 more source